Valiant Laboratories IPO

Valiant Laboratories Limited

₹13,965 /105 sharesMinimum Investment

Valiant Laboratories IPO Listing Details

Listed OnIssue PriceListing PriceListing Gains
BSE & NSE₹140.00₹162.00₹22.00 (15.71%)

Valiant Laboratories IPO Details

Bidding DatesMin. InvestmentLot SizePrice Range
27 Sep ‘23 - 3 Oct ‘23₹13,965105₹133 - ₹140
Issue SizeIPO Doc
152.46Cr
RHP PDF

Subscription Status As on 03 Oct '23, 5:00 PM

  • Qualified Institutional Buyers
    20.83x
  • Non-Institutional Investor
    73.63x
  • Retail Individual Investor
    16.04x
  • Employees
    0.00x
  • Total
    29.75x

About Valiant Laboratories

Valiant Laboratories is a company specializing in the production of Paracetamol, focusing on active pharmaceutical ingredients (API) and bulk drug manufacturing. It produces Paracetamol in various grades like IP, BP, EP, and USP, meeting the specific requirements of its customers as per pharmacopeia standards. Located in Maharashtra, India, their manufacturing facility spans 2,000 sq. mts. and has an annual installed capacity of 9,000 MT. ;
Parent Organisation
Valiant Laboratories Limited
Founded
2021
Managing Director
Mr. Santosh Shantilal Vora

Strengths & Risks

  • Between 2017 and 2023, the company saw a consistent increase in revenue from operations, with a compounded annual growth rate (CAGR) of 23.90%. Similarly, the restated profit after tax also exhibited growth, recording a CAGR of 26.81% during the same period.
  • The company’s quality control team monitors the manufacturing process at all stages, from the initial testing stage for incoming raw material to the final product before packing.
  • In terms of sourcing raw materials, Valiant Laboratories imports Para Amino Phenol, a crucial component for Paracetamol manufacturing, from suppliers in China and Cambodia. The company has reduced its dependence on external suppliers. Instead, it now procures this essential raw material through its promoter group company, Valiant Organics Limited.
  • Valiant Laboratories strategically positions its Manufacturing Facility, located approximately 150 kilometers away from JNPT (Nhava Sheva) Port in Navi Mumbai, Maharashtra. It is situated about 110 kilometers from the company's registered office in Mulund West, Mumbai, Maharashtra. It enables the company to have swift access to port facilities, facilitating the timely import of raw materials and efficient export of its products.
  • Any fluctuations or changes in the paracetamol API industry or shifts in product demand could have a detrimental effect on Valiant Laboratories' revenue and overall financial performance.
  • Valiant Laboratories operates solely from a single manufacturing facility situated in Palghar, Maharashtra. Any localized social unrest, natural disasters, service breakdowns, or disruptions in production at this facility could significantly harm the company's business and financial condition.
  • The company relies on a limited number of suppliers for its raw materials, primarily concentrated in the western region of India.
  • The company's revenue is heavily dependent on a small number of customers. The absence of long-term arrangements with these customers poses a risk, as any failure to continue existing arrangements could negatively affect the business and operational results.
  • Exposure to counterparty credit risk means that delays or non-receipt of payments could have an adverse impact on the company's operational results.
  • The company faces potential adverse effects on its results of operations due to fluctuations in exchange rates, particularly as it engages in exports and incurs expenses in foreign currencies.
  • The company, its promoters, and its directors are involved in certain legal proceedings. Unfavorable outcomes in these cases could harm the company's reputation, business, financial condition, and cash flows.

Financials

*All values are in Rs. Cr
No Graph Data To Display

Application details

Apply asPrice bandApply upto
Regular133 - 140₹2 Lakh
High Networth Individual133 - 140₹2 - 5 Lakh
For Valiant Laboratories IPO, eligible investors can apply as Regular.
ⓒ 2016-2023 Groww. All rights reserved, Built with in India
MOST POPULAR ON GROWWVERSION - 4.5.1
STOCK MARKET INDICES:  S&P BSE SENSEX |  S&P BSE 100 |  NIFTY 100 |  NIFTY 50 |  NIFTY MIDCAP 100 |  NIFTY BANK |  NIFTY NEXT 50
MUTUAL FUNDS COMPANIES:  GROWWMF |  SBI |  AXIS |  HDFC |  UTI |  NIPPON INDIA |  ICICI PRUDENTIAL |  TATA |  KOTAK MAHINDRA |  DSP |  CANARA ROBECO |  SUNDARAM |  MIRAE ASSET |  BANDHAN |  FRANKLIN TEMPLETON |  PPFAS |  MOTILAL OSWAL |  INVESCO |  EDELWEISS |  ADITYA BIRLA SUN LIFE |  LIC |  HSBC |  NAVI |  QUANTUM |  UNION |  IDBI |  ITI |  MAHINDRA MANULIFE |  360 ONE |  BOI |  TAURUS |  JM FINANCIAL |  PGIM |  SHRIRAM |  BARODA BNP PARIBAS |  QUANT |  WHITEOAK CAPITAL |  TRUST |  SAMCO |  NJ |  BAJAJ

ABOUT GROWW